CHOP Dosing for Lymphoma
The standard CHOP regimen should be administered every 21 days (CHOP-21) for 6-8 cycles, with each cycle consisting of cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² (capped at 2 mg), and prednisone 100 mg daily for 5 days. 1
Standard Dosing Schedule
The ESMO guidelines establish CHOP-21 as the backbone regimen, typically combined with rituximab (R-CHOP) for B-cell lymphomas. The specific dosing parameters are:
- Cyclophosphamide: 750 mg/m² IV on day 1
- Doxorubicin: 50 mg/m² IV on day 1
- Vincristine: 1.4 mg/m² IV on day 1
- Prednisone: 100 mg orally days 1-5
Cycles are repeated every 21 days 1
Number of Cycles by Patient Population
Young, Low-Risk Patients (aa-IPI = 0, no bulky disease)
- 6 cycles of R-CHOP-21 is the current standard 1
Young Low-Intermediate Risk or Bulky Disease (aa-IPI = 1)
- 6 cycles of R-CHOP-21 with radiotherapy to bulky sites 1
Young High-Risk Patients (aa-IPI ≥ 2)
- 6-8 cycles of R-CHOP-21 are most frequently applied 1
Patients Aged 60-80 Years
- 6-8 cycles of R-CHOP-21 is the current standard 1
Alternative Dosing: CHOP-14 (Dose-Dense)
CHOP administered every 14 days with G-CSF support did NOT demonstrate survival advantage over CHOP-21 in randomized trials 1. The ESMO guidelines explicitly state this regimen failed to show better outcomes in any DLBCL subset, including young poor-risk patients.
However, if CHOP-14 is used:
- 6 cycles of CHOP with 8 cycles of rituximab are sufficient 1
- Requires prophylactic G-CSF support starting day 2-3 2, 3, 4
Critical Dosing Principles
Avoid Dose Reductions
Dose reductions due to hematological toxicity should be avoided whenever possible 1. This is a Level I, Grade A recommendation. Maintaining relative dose intensity above 95% is crucial for optimal outcomes 2, 4.
G-CSF Prophylaxis
Prophylactic G-CSF is justified for:
- All patients treated with curative intent
- All patients >60 years of age 1
This prevents febrile neutropenia and maintains dose intensity.
Special Populations
Patients >80 Years
- R-miniCHOP (attenuated doses) can induce complete remission in fit elderly patients 1
- Consider doxorubicin substitution or omission in patients with cardiac dysfunction or frailty 1
- Geriatric assessment should guide treatment intensity 1
High Tumor Burden
- Administer prednisone prephase treatment several days before CHOP to prevent tumor lysis syndrome 1
Common Pitfalls to Avoid
Do not reduce doses for neutropenia - use G-CSF support instead to maintain schedule and intensity 1
Do not assume CHOP-14 is superior - despite theoretical advantages of dose-dense therapy, randomized trials showed no survival benefit over CHOP-21 1
Do not omit G-CSF in elderly patients - febrile neutropenia risk is substantial and prophylaxis is evidence-based 1
Monitor cardiac function before treatment - doxorubicin cumulative doses ≥250 mg/m² carry significant cardiotoxicity risk 5
Consider CNS prophylaxis in high-risk patients (high-intermediate/high IPI, >1 extranodal site, elevated LDH, testicular/renal/adrenal involvement) using high-dose IV methotrexate 1